Rhythm Pharmaceuticals Inc stock is traded at $112.36, with a volume of 1,498,941. It is down -3.80% in the last 24 hours and up +24.57% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Previous Close:
$116.80
Open:
$115.46
24h Volume:
1,498,941
Relative Volume:
1.15
Market Cap:
$7.79B
Revenue:
$217.17M
Net Income/Loss:
-$202.68M
P/E Ratio:
-
EPS:
-$2.30
Net Cash Flow:
-$156.63M
1W Performance:
-2.31%
1M Performance:
+24.57%
6M Performance:
+23.96%
1Y Performance:
+11.62%
1-Day Range:
$112.00$117.01
1-Week Range:
$104.20$121.41
52-Week Range:
$74.50$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
857-264-4280Address
222 BERKELEY STREET, BOSTON, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS